肺癌----课件1.pptVIP

* The graph shows 1- and 2-year survival in 563 patients with stage I-IIIB NSCLC randomized to receive either conventional radiotherapy (30 fractions of 2 Gray, reaching a total of 60 Gray in 6 weeks) or continuous hyperfractionated accelerated radiotherapy (CHART, 36 fractions of 1.5 Gray given three times daily, reaching a total of 54 Gray in 12 days).1 In this trial, CHART significantly improved survival compared with conventional radiotherapy.1 However, CHART was associated with a higher incidence of dysphagia1, and its value in routine practice has yet to be determined. 1. Saunders M, et